MedsChat.com
The People's Medicine Community ®

Zavesca

Active Ingredient(s): Miglustat
FDA Approved: July 31, 2003
Pharm Company: ACTELION PHARMS
Category: Enzymes



Zavesca Overview

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I Gaucher disease (GD1). It is marketed under the trade name Zavesca. Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Mechanism of action 5 Physical and chemical properties 6 Research 7 See also 8 References Medical uses Miglustat is used to treat adults with mild-to-moderate type I Gaucher disease for whom enzyme re...

Read more Zavesca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Miglustat

Recent Zavesca Forums: RSS Feed

zavesca
Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nausea, back pain, constipation and weight loss. You can read more here: Do you have any other questions?
Updated 5 years ago.
   1  RSS Feed for thread 195345

Possible Dosages for this and Related Drugs:

Miglustat
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Miglustat or a similar ingredient: (1 result)


Possibly related Zavesca Topics:

zavesca Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nause...  1